Related Experiment Videos
Adjuvant hormone therapy following primary therapy for endometrial cancer
S Loibl1, G von Minckwitz, M Kaufmann
1Universitätsfrauenklinik, Theodor-Stern-Kai 7, Frankfurt am Main, Germany. loibl@em.uni-frankfurt.de
European Journal of Cancer (Oxford, England : 1990)
|November 1, 2002
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.
Annals of oncology : official journal of the European Society for Medical Oncology·2021
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
Annals of oncology : official journal of the European Society for Medical Oncology·2019
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Annals of oncology : official journal of the European Society for Medical Oncology·2018
Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
Breast cancer research and treatment·2017
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2017
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.
Breast cancer research and treatment·2017
Association of immune and proliferation gene signatures and stromal tumor-infiltrating lymphocytes with clinical outcomes in patients with stage I triple-negative breast cancer.
European journal of cancer (Oxford, England : 1990)·2026
Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?
European journal of cancer (Oxford, England : 1990)·2026
Natural history and treatment outcomes in aggressive angiomyxoma: A single institution experience.
European journal of cancer (Oxford, England : 1990)·2026
Diagnostic pitfalls and unmet needs in neuroendocrine neoplasms: The added value of collegial expert pathology review through the national TENpath network.
European journal of cancer (Oxford, England : 1990)·2026
Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen.
European journal of cancer (Oxford, England : 1990)·2026
Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.
European journal of cancer (Oxford, England : 1990)·2026
Introducing "HEDGE": sequential intravesical gemcitabine-based thermochemotherapy (HIVEC) plus docetaxel as a potential novel bladder-sparing strategy for BCG-unresponsive non-muscle-invasive bladder cancer.
Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica·2026
Surgical Fasciectomy Versus Collagenase Injection for Recurrent Dupuytren Contracture: A Randomized Controlled Trial.
Plastic and reconstructive surgery·2026
Ustekinumab combined with upadacitinib promotes endoscopic healing in moderate-to-severe Crohn's disease with anti-TNF-α failure.
Revista espanola de enfermedades digestivas·2026
Cholecystostomy-tube cholangiography guiding ERCP for bile duct stones after pancreaticoduodenectomy.
Revista espanola de enfermedades digestivas·2026